本帖最后由 老马 于 2012-1-13 21:20 编辑
! B& T8 Y8 g. m: j0 ?) G v3 H r
) |9 A, B! U# @6 v g; t; E0 O( t爱必妥和阿瓦斯丁的比较! f" R4 s+ e$ _ [9 @" a7 o ?
! A, R s0 b' E8 f7 Z# J* z7 Ohttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
$ x" o& O6 X3 h/ t- R/ U, f
; E( g4 M- x' B
& V' u9 z+ {' R5 z% ?( g9 h
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
" l0 f# a9 `* S# F==================================================6 |1 G: L2 O( e- E0 J
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
8 K- ?. K, M: T5 |9 PPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
e$ s8 G5 X: t0 EResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported." B! Z3 H- S2 e0 H s+ u
|